The global ezetimibe market is anticipated to grow at a CAGR of nearly 5.2% during the forecast period (2022-2028). The ezetimibe drug has been approved for use in children aged 10-17 years with cholesterol levels of 500mg/dL or greater, which had previously been limited to those aged 18 and above. In addition, the market is […]
